{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["47(4)"],"submitter":["Mazaherioun M"],"pubmed_abstract":["<h4>Background</h4>Type 2 diabetes mellitus (T2DM) is commonly associated with depressive symptoms, which affect prognosis and quality of life. We investigated the antidepressant effects of n-3 fatty acids (n-3FAs) monotherapy (without conventional antidepressants) for T2DM patients with mild to moderate depressive symptoms.<h4>Methods</h4>A 10-wk, placebo-controlled, double-blind, parallel-group (1:1 ratio) randomized trial of n-3FAs (2700 mg/day EPA: DHA ratio=2) versus placebo in 88 Iranian diabetic patients with mild to moderate depression based on Beck Depression Inventory II (BDI-II-PERSIAN) was conducted. This study started from July 2014 to January 2015 in Tehran University of Medical Sciences, Tehran, Iran. The primary event was defined as worsened, non-changed, or inconsiderably improved depression (<5 unit decrease in BDI-II-PERSIAN depression scores after treatment) (ClinicalTrials.gov Identifier: NCT02261545).<h4>Results</h4>Randomly, 44 T2DM patients were treated with n-3FAs supplements and 44 cases received placebo (three patients discontinued). n-3FAs could significantly protect patients against the aforesaid event and exhibit satisfactory prevention (number needed to treat with 95% confidence interval: 2.52, 1.71-4.74). No serious adverse reactions were reported.<h4>Conclusion</h4>n-3FAs supplementation had significant antidepressant effects in T2DM patients with mild to moderate depressive symptoms, not confounded by metabolic factors and disease duration."],"journal":["Iranian journal of public health"],"pagination":["575-583"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5996325"],"repository":["biostudies-literature"],"pubmed_title":["Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus."],"pmcid":["PMC5996325"],"pubmed_authors":["Zarei M","Djalali M","Koohdani F","Mazaherioun M","Javanbakht MH","Ansari S","Saedisomeolia A","Khoshkhoo Bazargani F"],"additional_accession":[]},"is_claimable":false,"name":"Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus.","description":"<h4>Background</h4>Type 2 diabetes mellitus (T2DM) is commonly associated with depressive symptoms, which affect prognosis and quality of life. We investigated the antidepressant effects of n-3 fatty acids (n-3FAs) monotherapy (without conventional antidepressants) for T2DM patients with mild to moderate depressive symptoms.<h4>Methods</h4>A 10-wk, placebo-controlled, double-blind, parallel-group (1:1 ratio) randomized trial of n-3FAs (2700 mg/day EPA: DHA ratio=2) versus placebo in 88 Iranian diabetic patients with mild to moderate depression based on Beck Depression Inventory II (BDI-II-PERSIAN) was conducted. This study started from July 2014 to January 2015 in Tehran University of Medical Sciences, Tehran, Iran. The primary event was defined as worsened, non-changed, or inconsiderably improved depression (<5 unit decrease in BDI-II-PERSIAN depression scores after treatment) (ClinicalTrials.gov Identifier: NCT02261545).<h4>Results</h4>Randomly, 44 T2DM patients were treated with n-3FAs supplements and 44 cases received placebo (three patients discontinued). n-3FAs could significantly protect patients against the aforesaid event and exhibit satisfactory prevention (number needed to treat with 95% confidence interval: 2.52, 1.71-4.74). No serious adverse reactions were reported.<h4>Conclusion</h4>n-3FAs supplementation had significant antidepressant effects in T2DM patients with mild to moderate depressive symptoms, not confounded by metabolic factors and disease duration.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2025-04-22T12:43:22.341Z","creation":"2019-03-26T23:41:42Z"},"accession":"S-EPMC5996325","cross_references":{"pubmed":["29900143"]}}